News Center

BB102, a highly selective and potent reversible-covalent FGFR4 inhibitor effective in multiple xenograft tumor models

Time of issue：

2024-04-07

Author:

BroadenBio

Origin:

BroadenBio

previous page

none

BB5523, a multiple kinase inhibitor with HPK1, VEGFR2 and TNIK inhibition, enhanced antitumor immunity in tumor models

next page

previous page

none

next page

BB5523, a multiple kinase inhibitor with HPK1, VEGFR2 and TNIK inhibition, enhanced antitumor immunity in tumor models

address：

A1-602, 88 Kechuang 6th Street, BDA, Beijing 100176

phone：

010-58222729

e-mail：

hr@broadenbio.com

 

Copyright ©2019 BroadenBio

SEO

Powered by www.300.cn

business license